Sintilimab - Eli Lilly

Drug Profile

Sintilimab - Eli Lilly

Alternative Names: Anti-PD-1-antibody-Cinda; IBI-308; Sintilimab - Eli Lily/Innovent

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovent Biologics
  • Developer Cinda Biopharmaceutical; Eli Lilly; Innovent Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hodgkin's disease
  • Phase III Non-small cell lung cancer
  • Phase I Solid tumours
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 25 Jun 2018 Innovent Biologics plans a phase Ib trial for Solid malignancies (Late stage disease, Metastatic, IV) (NCT03568539)
  • 01 Jun 2018 Efficacy, adverse events and pharmacokinetic data from a phase I trial in advanced Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 01 Jun 2018 Efficacy and adverse events data from a phase II ORIENT I trial in Hodgkin's disease (Relapsed or refectory) presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO- 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top